As previously reported, Guggenheim downgraded Exelixis (EXEL) to Neutral from Buy and removed the firm’s previous $45 price target on the shares. Noting that the stock nearly doubled over the last two years, the firm believes the share price now reflects fair value for the Cabometyx franchise and pipeline. In addition, the firm believes visibility on new growth drivers after the 2030 patent cliff remains low.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis downgraded to Neutral from Buy at Guggenheim
- EXEL Earnings this Week: How Will it Perform?
- Exelixis’s Strategic Positioning and Market Prospects Justify Buy Rating Amid RCC Treatment Dynamics
- Buy Rating Affirmed for Exelixis: Promising Phase 3 Trial Results and Favorable Valuation Despite Safety Concerns
- Apple, MARA, Exelixis, Strategy, Dell: Trending by Analysts